Receptor for advanced glycation end-products and ARDS prediction: A multicentre observational study

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Jabaudon, Matthieu ^a,b   Berthelin, Pauline ^a   Pranal, Thibaut ^a   Roszyk, Laurence ^a,b   Godet, Thomas ^a   Faure, Jean Sébastien ^a   Chabanne, Russell ^a   Eisenmann, Nathanael ^c   Lautrette, Alexandre ^b   Belville, Corinne ^b   Blondonnet, Raiko ^a,b   Cayot, Sophie ^a   Gillart, Thierry ^a   Pascal, Julien ^a   Skrzypczak, Yvan ^c   Souweine, Bertrand ^b   Blanchon, Loic ^b   Sapin, Vincent ^a,b   Pereira, Bruno ^a   Constantin, Jean Michel ^a,b  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c Jean Perrin Cancer Centre   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; ESRAGE PROTEIN, HUMAN; SRAGE PROTEIN, HUMAN;

ADULT RESPIRATORY DISTRESS SYNDROME; AGED; BLOOD; CLINICAL TRIAL; FEMALE; GENETICS; HUMAN; INTENSIVE CARE UNIT; MALE; MIDDLE AGED; MULTICENTER STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BIOMARKERS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 85041824419     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-20994-x     Document Type: Article

References (48)

1. ARDS Definition, T. F. et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 307, 2526-2533 (2012).
2. Bellani, G. et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA 315, 788-800 (2016).
3. Neto, A. S. et al. Epidemiological characteristics, practice of ventilation, and clinical outcome in patients at risk of acute respiratory distress syndrome in intensive care units from 16 countries (PRoVENT): an international, multicentre, prospective study. Lancet Respir Med 4, 882-893 (2016).
4. Yadav, H., Thompson, B. T. & Gajic, O. Fifty Years of Research in ARDS. Is Acute Respiratory Distress Syndrome a Preventable Disease? Am. J. Respir. Crit. Care Med. https://doi.org/10.1164/rccm.201609-1767CI (2016)
5. Pham, T. & Rubenfeld, G. D. Fifty Years of Research in ARDS. The Epidemiology of ARDS: A Fiftieth Birthday Review. Am. J. Respir. Crit. Care Med. https://doi.org/10.1164/rccm.201609-1773CP (2017).
6. Matthay, M. A., McAuley, D. F. & Ware, L. B. Clinical trials in acute respiratory distress syndrome: challenges and opportunities. The Lancet Respiratory Medicine 5, 524-534 (2017).
7. Gajic, O. et al. Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am. J. Respir. Crit. Care Med. 183, 462-470 (2011).
8. Agrawal, A. et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am. J. Respir. Crit. Care Med. 187, 736-742 (2013).
9. Uchida, T. et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am. J. Respir. Crit. Care Med. 173, 1008-1015 (2006).
10. Uchida, T. et al. Soluble isoform of the receptor for advanced glycation end products as a biomarker for postoperative respiratory failure after cardiac surgery. PLoS One 8, e70200 (2013).
11. Cohen, M. J. et al. Early release of soluble receptor for advanced glycation endproducts after severe trauma in humans. J. Trauma 68, 1273-1278 (2010).
12. Jabaudon, M. et al. Association between intraoperative ventilator settings and plasma levels of soluble receptor for advanced glycation end-products in patients without pre-existing lung injury. Respirology https://doi.org/10.1111/resp.12583 (2015).
13. Zhang, L. et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J. Biol. Chem. 283, 35507-35516 (2008).
14. Cheng, C. et al. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod. Pathol. 18, 1385-1396 (2005).
15. Hudson, B. I. et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 22, 1572-1580 (2008).
16. Calfee, C. S. et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 63, 1083-1089 (2008).
17. Jabaudon, M. et al. Soluble Receptor for Advanced Glycation End-Products Predicts Impaired Alveolar Fluid Clearance in Acute Respiratory Distress Syndrome. Am. J. Respir. Crit. Care Med. 192, 191-199 (2015).
18. Jabaudon, M. et al. Soluble Forms and Ligands of the Receptor for Advanced Glycation End-Products in Patients with Acute Respiratory Distress Syndrome: An Observational Prospective Study. PLoS One 10, e0135857 (2015).
19. Meyer, N. J. Future clinical applications of genomics for acute respiratory distress syndrome. Lancet Respir Med 1, 793-803 (2013).
20. Meyer, N. J. Beyond single-nucleotide polymorphisms: genetics, genomics, and other'omic approaches to acute respiratory distress syndrome. Clin. Chest Med. 35, 673-684 (2014).
21. Meyer, N. J. & Christie, J. D. Genetic heterogeneity and risk of acute respiratory distress syndrome. Semin. Respir. Crit. Care Med. 34, 459-474 (2013).
22. Reilly, J. P., Christie, J. D. & Meyer, N. J. Fifty Years of Research in ARDS. Genomic Contributions and Opportunities. Am. J. Respir. Crit. Care Med. https://doi.org/10.1164/rccm.201702-0405CP (2017).
23. Matthay, M. A. Resolution of pulmonary edema. Thirty years of progress. Am. J. Respir. Crit. Care Med. 189, 1301-1308 (2014).
24. Thompson, B. T., Chambers, R. C. & Liu, K. D. Acute Respiratory Distress Syndrome. N. Engl. J. Med. 377, 562-572 (2017).
25. Beitler, J. R., Schoenfeld, D. A. & Thompson, B. T. Preventing ARDS: Progress, Promise, and Pitfalls. Chest 146, 1102-1113 (2014).
26. Li, G. et al. Eight-year trend of acute respiratory distress syndrome: a population-based study in Olmsted County, Minnesota. Am. J. Respir. Crit. Care Med. 183, 59-66 (2011).
27. Briot, R. et al. Elevated levels of the receptor for advanced glycation end products, a marker of alveolar epithelial type I cell injury, predict impaired alveolar fluid clearance in isolated perfused human lungs. Chest 135, 269-275 (2009).
28. Blondonnet, R. et al. RAGE inhibition reduces acute lung injury in mice. Sci. Rep. 7, 7208 (2017).
29. Santilli, F., Vazzana, N., Bucciarelli, L. G. & Davì, G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr. Med. Chem. 16, 940-952 (2009).
30. Gopal, P. et al. Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD. Respir. Res. 15, 24 (2014).
31. Yamamoto, Y. et al. Assaying Soluble Forms of Receptor for Advanced Glycation End Products. Arterioscler. Thromb. Vasc. Biol. 27, e33-e34 (2007).
32. Jabaudon, M. et al. Effects of a recruitment maneuver on plasma levels of soluble RAGE in patients with diffuse acute respiratory distress syndrome: a prospective randomized crossover study. Intensive Care Med. 41, 846-855 (2015).
33. Hofmann, M. A. et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 3, 123-135 (2002).
34. Krishnan, S., Ravi, S., Ponmalai, S. & Rani, P. A Molecular Dynamics Study on RAGE-Aβ42 Interaction and the Influence of G82S RAGE Polymorphism on AβInteraction. Int J Bioautomation 19, 433-446 (2015).
35. Hudson, B. I., Stickland, M. H., Futers, T. S. & Grant, P. J. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50, 1505-1511 (2001).
36. Jang, Y. et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism 56, 199-205 (2007).
37. Cheng, D. T. et al. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 188, 948-957 (2013).
38. Calfee, C. S. et al. Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies. Chest 147, 1539-1548 (2015).
39. Famous, K. R. et al. Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy. Am. J. Respir. Crit. Care Med. 195, 331-338 (2017).
40. Bos, L. D. et al. Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax https://doi.org/10.1136/thoraxjnl-2016-209719 (2017).
41. Prescott, H. C., Calfee, C. S., Thompson, B. T., Angus, D. C. & Liu, V. X. Towards Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and ARDS Clinical Trial Design. Am. J. Respir. Crit. Care Med. https://doi.org/10.1164/rccm.201512-2544CP (2016).
42. Matthay, M. A. Challenges in predicting which patients will develop ARDS. Lancet Respir Med 4, 847-848 (2016).
43. von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J. Clin. Epidemiol. 61, 344-349 (2008).
44. Pettersson-Fernholm, K. et al. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 52, 891-894 (2003).
45. Martens, H. A. et al. Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis. Lupus 21, 959-968 (2012).
46. Le Gall, J. R., Lemeshow, S. & Saulnier, F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270, 2957-2963 (1993).
47. Hardy, G. H. Mendelian proportions in a mixed population. Science 28, 49-50 (1908).
48. Cleves, M. Hardy-Weinberg equilibrium test and allele frequency estimation. Stata Technical Bulletin 8 (1999).